Can you point to any negative news? This is an under financed bio tech that could have a blockbuster drug in depression.
The NIH liked it enough to phase 2a trial and the results should be published Q1. I know for a fact that some of the biggest Pharma companies have their eyes on this company. If the NIH study shows it is safe the next step is the efficacy in an adjunctive phase 2 trial.
There are no guarantees, but if that trial is a success this will be 20 to 30 dollars and companies will be throwing money at them.
Only about 15 months for results, that is super fast in the biotech world.
News 
Market Data 
Discover 
